Gilles Gallant

Company: Mythic Therapeutics

Job title: Chief Development Officer

Seminars:

MYTX-011, a cMET-Targeting Antibody-Drug Conjugate (ADC), In Patients with Advanced NSCLC: Dose Escalation Results In The Phase 1 Kismet-01 Study 8:00 am

Examining the safety and tolerability of MYTX-011 in patients with advanced NSCLC Evaluating the PK of MYTX-011 in patients with advanced NSCLC Analyzing the preliminary efficacy of MYTX-011 in patients with advanced NSCLCRead more

day: Scientific Program Day One AM